|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Furthermore, combined treatment with l-α-dimyristoylphosphatidylcholine liposome and the glucosylceramide synthase inhibitor D-PDMP induced cell death in association with ceramide accumulation and promoted cancer cell apoptosis and tumor regression in murine models.
|
26650179 |
2016 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Inhibition of glucosylceramide synthase with d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) sensitized p53-R273H cancer cells and tumor xenografts to doxorubicin treatments.
|
27517620 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Of interest, GCS inhibition improved sorafenib effectiveness in a xenograft mouse model, recovering drug sensitivity of sorafenib-resistant tumors in mice.
|
26811497 |
2016 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
GCS expression was significantly upregulated in NSCLC tumors compared with non-cancerous tissue.
|
25189947 |
2014 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
GCS overexpression was associated with primary tumor size, local infiltration, lymph node metastasis, and local recurrence, but not associated with gender, age, pathological variants, tumor multifocality, tumor stage or distant metastasis.
|
24342307 |
2013 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
GCS levels were analyzed using cancer profiling arrays, breast cancer histo-arrays and quantitative RT-PCR in tumor tissues.We found that breast (18 exp. index) and other hormone-dependent organs (testis, cervix, ovary, prostate) displayed the lowest levels of GCS mRNA, whereas liver (52 exp. index) and other organs (kidney, bladder, stomach) displayed the highest levels of GCS.
|
21617856 |
2011 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
This method has been used successfully to evaluate the degrees of GCS enzyme in cells and in tumors subjected to gene manipulation and chemical inhibition.
|
19826105 |
2010 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In univariate analysis there was a benefit for disease free survival for patients with tumors displaying low levels of GCS expression but this significance was lost in multivariate Cox regression.
|
18560890 |
2009 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Collectively, these findings provide the framework for clinical evaluation of GCS-100, either alone or in combination with dexamethasone, to inhibit tumor growth, overcome drug resistance, and improve outcome for patients with this universally fatal hematologic malignancy.
|
16166312 |
2005 |